Puma Biotechnology, Inc.
PBYIHealthcareNASDAQBiotechnology · Last scanned Jul 16, 2026
Scan Results
Daily timeframePuma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company carries a $428.1M market cap, placing it firmly in the small-cap category. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Market Cap
$428.1M
Beta
1.19
P/E (TTM)
17.52
P/E (Fwd)
24.03
EPS (TTM)
$0.48
EPS (Fwd)
$0.35
ROE
21.6%
ROA
9.5%
Cash
$101.5M
Total Debt
$16.0M
Free CF
$44.1M
52W Change
144.5%
Annual Financials
Cash vs Debt
With $101.5M in cash and $16.0M in debt, PBYI maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $44.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 21.6%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 9.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $228.0M (2022) to $228.4M (2025).
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PBYI.